Tin tức & Cập nhật

In patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations*, combining niraparib with abiraterone acetate plus prednisone (AAP) in the first-line setting improved radiographic progression-free survival (rPFS) and other outcomes, results of the phase III MAGNITUDE study showed.

In the phase II TITAN-TCC* trial presented at ASCO GU 2022, the addition of ipilimumab to nivolumab led to improved responses in patients with pretreated (second/third line) advanced/metastatic or surgically unresectable transitional cell carcinoma (TCC).

In individuals with advanced urothelial carcinoma (UC), a first-line maintenance treatment regimen comprising a combination of avelumab and best supportive care (BSC) provided better survival benefit than BSC alone, according to long-term and subgroup analyses of the phase III JAVELIN Bladder 100 trial presented at ASCO GU 2022.

In Gleason grade group (GGG) 3 prostate cancer patients with a single intermediate-risk positive biopsy core, risk downgrading appears to be more likely than upgrading, reports a new study.

A recent study has shown clear preferences by urologists when providing postoperative immediate chemotherapy in nonmuscle invasive bladder cancer (NMIBC). Factors beyond clinical variables, such as the structure of the recovery room, play a role in this decision-making process.